keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal implant

keyword
https://www.readbyqxmd.com/read/29770638/factors-associated-with-pain-following-intravitreal-injections
#1
Seong Hwan Shin, Sung Pyo Park, Yong Kyu Kim
PURPOSE: To investigate factors associated with pain intensity following intravitreal injection and factors that might be associated with changes in pain intensity in patients who received repeated injections. METHODS: A total of 172 eyes (147 patients) were prospectively enrolled. Patients rated their pain from 0 to 10 using a visual analogue scale. Multiple linear regression analysis was used to evaluate factors associated with pain score. Sixty-eight patients evaluated their degree of pain more than once and were divided into three groups according to changes in pain during repeated injections...
May 15, 2018: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/29750012/ahmed-glaucoma-valve-in-uveitic-patients-with-fluocinolone-acetonide-implant-induced-glaucoma-3-year-follow-up
#2
Buraa Kubaisi, Arash Maleki, Aseef Ahmed, Neel Lamba, Haitham Sahawneh, Andrew Stephenson, Alyssa Montieth, Shobha Topgi, C Stephen Foster
Purpose: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) in eyes with noninfectious uveitis that had fluocinolone acetonide intravitreal implant (Retisert™)-induced glaucoma. Methods: This retrospective study reviewed the safety and efficacy of AGV implantation in patients with persistently elevated intraocular pressure (IOP) after implantation of a fluocinolone acetonide intravitreal implant at the Massachusetts Eye Research and Surgery Institution between August 2006 and November 2015...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29744040/recent-advances-in-understanding-and-managing-retinal-vein-occlusions
#3
REVIEW
Daniel D Esmaili, David S Boyer
Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery...
2018: F1000Research
https://www.readbyqxmd.com/read/29729900/design-of-hollow-hyaluronic-acid-cylinders-for-sustained-intravitreal-protein-delivery
#4
Erik Van Kampen, Craig Vandervelden, Amir Fakhari, Jian Qian, Cory Berkland, Stevin H Gehrke
A hollow cylinder intravitreal implant was developed to achieve sustained release of protein to the retina for the treatment of retinal diseases. Hollow cylinders were fabricated by molding and crosslinking hyaluronic acid (HA), the major component of the vitreous humor. Hollow cylinders were filled with a concentrated protein solution and the properties of the cylinder walls were tested. Crosslinked HA hydrogels with swelling degrees as low as 2.7 were achieved as a means to extend the release of protein. Hollow cylinders were capable of releasing an antigen-binding fragment (Fab) for over 4 months at a maximum release rate of 4 micrograms a day...
May 3, 2018: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29708803/a-5-year-follow-up-study-of-the-treatment-of-macular-edema-due-to-retinal-vein-occlusion-using-dexamethasone-intravitreal-implants
#5
Gonzaga Garay-Aramburu, Ángela Gómez-Moreno
PURPOSE: To evaluate the long-term effects of intravitreal dexamethasone implants (IDIs) in eyes with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We reviewed the records of 10 patients followed for 5 years after they received their first IDI. The main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and central macular volume (CMV), and the incidence of side effects. RESULTS: Ten patients were included in the study with a mean follow-up of 65...
April 30, 2018: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29670789/repeat-intravitreal-dexamethasone-implant-for-refractory-cystoid-macular-edema-in-syphilitic-uveitis
#6
Cassandra C Lautredou, Joshua S Hardin, John R Chancellor, Sami H Uwaydat, Abdallah A Ellabban, Ahmed B Sallam
Purpose: To report the successful utilization of adjunctive repeat intravitreal corticosteroid therapy for the treatment of cystoid macular edema in syphilis-related uveitis. Methods/Patients: An HIV-positive patient with treated ocular syphilis who developed refractory cystoid macular edema (CME) was treated with repeat intravitreal corticosteroid therapy including dexamethasone intravitreal implants. Results: Treatment led to the resolution of CME and improvement in visual acuity...
2018: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/29669176/anti-vascular-endothelial-growth-factor-combined-with-intravitreal-steroids-for-diabetic-macular-oedema
#7
REVIEW
Hemal Mehta, Charles Hennings, Mark C Gillies, Vuong Nguyen, Anna Campain, Samantha Fraser-Bell
BACKGROUND: The combination of steroid and anti-vascular endothelial growth factor (VEGF) intravitreal therapeutic agents could potentially have synergistic effects for treating diabetic macular oedema (DMO). On the one hand, if combined treatment is more effective than monotherapy, there would be significant implications for improving patient outcomes. Conversely, if there is no added benefit of combination therapy, then people could be potentially exposed to unnecessary local or systemic side effects...
April 18, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29643797/uneventful-anterior-migration-of-intravitreal-ozurdex-implant-in-a-patient-with-iris-sutured-intraocular-lens-and-descemet-stripping-automated-endothelial-keratoplasty
#8
Andleeb Zafar, Ioannis M Aslanides, Vasileios Selimis, Konstantinos I Tsoulnaras, David Tabibian, George D Kymionis
Purpose: We report here the case of a patient with anterior segment migration of intravitreal dexamethasone implant as well as its management and outcome. Methods: The patient had the following sequence of events: complicated cataract surgery, iris-sutured intraocular lens implant, followed by cystoid macular edema treated with intravitreal Avastin, retinal vein occlusion treated with intravitreal dexamethasone implant, corneal decompensation treated with Descemet stripping automated endothelial keratoplasty (DSAEK), and finally recurrence of macular edema treated with repeated intravitreal dexamethasone implant...
January 2018: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29617689/clinical-decision-making-when-treating-diabetic-macular-edema-patients-with-dexamethasone-intravitreal-implants
#9
Alfredo García-Layana, Marta S Figueroa, Luis Arias, Alfredo Adán, Francisco Cabrera, Maximino Abraldes, Álvaro Fernández-Vega, Rafael Navarro, Enrique Cervera, Rufino Silva, Felix Armadá, Juan Donate, José Maria Ruiz-Moreno
Diabetes mellitus (DM) is a metabolic disease frequently associated with comorbidities that include diabetic macular edema (DME). The current medical approach to treating DME involves intravitreal injections with either anti-vascular endothelial growth factors or steroids. However, the burden associated with intravitreal injections and DM-derived complications is high, underlining the need to find optimal treatment regimens. In this article we describe the considerations we apply when treating DME patients with dexamethasone intravitreal implants (Ozurdex®), particularly those that influence the clinical decision-making process during the follow-up period...
April 4, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29563700/fungal-keratitis-and-endophthalmitis-after-implantation-of-type-1-keratoprosthesis
#10
Chintan Malhotra, Arun Kumar Jain, Nikhil Aggarwal
A 70-year-old patient who underwent uneventful primary implantation of Auro K Pro (a Type I Boston Keratoprosthesis-based device), developed infiltrates in the deep stroma of the carrier corneal graft and exudates on the optic stem of the keratoprosthesis assembly, 6 weeks postoperatively, which subsequently progressed to endophthalmitis. Vitreous tap was positive for a panfungal polymerase chain reaction, although corneal scrapings for both Gram stain and KOH wet mount yielded negative results. Aggressive management with systemic, topical, intravitreal, and intrastromal antifungal agents resulted in an initial resolution, but residual inflammatory vitreous membranes persisted...
January 2018: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/29560616/prognostic-factors-for-functional-and-anatomic-outcomes-in-patients-with-diabetic-macular-edema-treated-with-dexamethasone-implant
#11
Hyungwoo Lee, Kyung Eun Kang, Hyewon Chung, Hyung Chan Kim
PURPOSE: To investigate the prognostic factors of visual and anatomic outcomes in patients with diabetic macular edema (DME) treated with intravitreal injection of dexamethasone implant. METHODS: We retrospectively studied 32 eyes of 31 patients with DME for best-corrected visual acuity (BCVA), central macular thickness, and height and width of both intraretinal fluid (IRF) and subretinal fluid. Logistic regression analysis was used to examine correlations between the baseline characteristics and outcomes at 3 and 6 months...
March 13, 2018: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/29550932/the-short-term-efficacy-of-intravitreal-ranibizumab-aflibercept-and-dexamethasone-implant-in-the-treatment-of-macular-edema-due-to-non-ischemic-central-retinal-vein-occlusion
#12
Ozlem Eski Yucel, Hakki Birinci, Yuksel Sullu
PURPOSE: To assess and compare the efficacy over 6 months of intravitreal ranibizumab (IR), aflibercept (IA) and dexamethasone implant (IDI) in eyes with macular edema (ME) secondary to non-ischemic central retinal vein occlusion (CRVO). METHODS: This is a retrospective single-center study. Patients who received pro re nata treatment of IR 0.5 mg, IA 2 mg or IDI 0.7 mg (as Group 1, Group 2, and Group 3, respectively) for the treatment of ME due to non-ischemic CRVO were included in the study...
March 17, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29533953/tissue-plasminogen-activator-as-an-antiangiogenic-agent-in-experimental-corneal-neovascularization-in-rabbits
#13
Kon-Ichi Arai, Tsutomu Yasukawa, Aki Kato, Ayae Kubota, Hideaki Usui, Noriaki Takase, Soichiro Kuwayama, Yuichiro Ogura
AIMS: Anti-vascular endothelial growth factor agents effectively treat age-related macular degeneration and myopic choroidal neovascularization (CNV). Tissue plasminogen activator (tPA), a fibrinolytic compound, is used as an adjuvant to displace submacular hemorrhage and to treat type 2 CNV. The purpose of this study was to investigate in in vitro and in vivo experiments the antiangiogenic impact of tPA itself. METHODS: The impact of tPA on the proliferation of human umbilical vein endothelial cells (HUVECs) was assessed by an XTT assay [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide]...
March 13, 2018: Ophthalmic Research
https://www.readbyqxmd.com/read/29516291/etoposide-loaded-poly-lactic-co-glycolic-acid-intravitreal-implants-in-vitro-and-in-vivo-evaluation
#14
Ana Gabriela Reis Solano, Adriana de Fátima Pereira, Luiz Gustavo Amorim de Faria, Silvia Ligório Fialho, Patrícia Santiago de Oliveira Patricio, Armando da Silva-Cunha, Gustavo Oliveira Fulgêncio, Gisele Rodrigues da Silva, Gérson Antônio Pianetti
Etoposide-loaded poly(lactic-co-glycolic acid) implants were developed for intravitreal application. Implants were prepared by a solvent-casting method and characterized in terms of content uniformity, morphology, drug-polymer interaction, stability, and sterility. In vitro drug release was investigated and the implant degradation was monitored by the percent of mass loss. Implants were inserted into the vitreous cavity of rabbits' eye and the in vivo etoposide release profile was determined. Clinical examination and the Hen Egg Test-Chorioallantoic Membrane (HET-CAM) method were performed to evaluate the implant tolerance...
May 2018: AAPS PharmSciTech
https://www.readbyqxmd.com/read/29505751/dexamethasone-intravitreal-implant-downregulates-pdgfr-%C3%AE-and-upregulates-caveolin-1-in-experimental-branch-retinal-vein-occlusion
#15
Lasse Jørgensen Cehofski, Anders Kruse, Sigriður Olga Magnusdottir, Alexander Nørgård Alsing, Jonas Ellegaard Nielsen, Svend Kirkeby, Bent Honoré, Henrik Vorum
A dexamethasone (DEX) intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a DEX implant this study combined an experimental model of BRVO with proteomic techniques. In eight Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser. After inducing BRVO a DEX implant was injected into the right eye of each animal while the left control eye was given an identical injection without an implant...
March 2, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29503947/juvenile-x-linked-retinoschisis-responsive-to-intravitreal-corticosteroids
#16
Waseem H Ansari, Andrew W Browne, Rishi P Singh
Purpose: To report the case of an adult male with X-linked retinoschisis (XLRS) who presented with cystoid macular edema (CME) that responded consistently to treatment with intravitreal steroids. Observations: A 39 year old male with unilateral presentation of CME after repair of a retinal detachment secondary to XLRS responded initially to an injection of intravitreal triamcinolone acetonide (IVTA). Central subfield thickness on OCT was reduced. Three months later, the CME recurred and he was unresponsive to topical treatment so repeat IVTA was given, and the CME once again was reduced dramatically...
April 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29497837/progression-of-diabetic-retinopathy-severity-after-treatment-with-dexamethasone-implant-a-24-month-cohort-study-the-dr-pro-dex-study
#17
Matias Iglicki, Dinah Zur, Catharina Busch, Mali Okada, Anat Loewenstein
PURPOSE: Intravitreal anti-vascular endothelial growth factor agents have been shown to reduce diabetic retinopathy (DR) progression; data on the effects of intravitreal corticosteroids on modifying disease severity are limited. This study evaluates the long-term effect of intravitreal dexamethasone implant (DEX) on the severity and progression of non-proliferative DR (NPDR). METHODS: This was a retrospective cohort study. Sixty eyes from 60 consecutive patients with NPDR and diabetic macular edema (DME) treated with dexamethasone implant (DEX group) and 49 eyes from consecutive 49 patients without DME requiring observation only...
March 1, 2018: Acta Diabetologica
https://www.readbyqxmd.com/read/29490233/influence-of-the-test-method-on-in-vitro-drug-release-from-intravitreal-model-implants-containing-dexamethasone-or-fluorescein-sodium-in-poly-d-l-lactide-co-glycolide-or-polycaprolactone
#18
Sandra Stein, Tobias Auel, Wiebke Kempin, Malte Bogdahn, Werner Weitschies, Anne Seidlitz
Sustained intravitreal dexamethasone (DX) administration with the FDA and EMA approved Ozurdex® implant is indicated for the treatment of macular edema and non-infectious uveitis. Since drug release after intravitreal application cannot be determined in vivo in human eyes, the characterization of drug release in vitro in addition to animal models is of great importance. The aim of this study was to provide information about the influence of the test method on the in vitro drug release from intravitreal model implants...
June 2018: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/29486754/treating-diabetic-macular-oedema-dmo-real-world-uk-clinical-outcomes-for-the-0-19mg-fluocinolone-acetonide-intravitreal-implant-iluvien%C3%A2-at-2-years
#19
William Fusi-Rubiano, Chandoshi Mukherjee, Mark Lane, Marie D Tsaloumas, Nicholas Glover, Andrej Kidess, Alastair K Denniston, Helen E Palmer, Avinash Manna, Rupal Morjaria
BACKGROUND: To compare visual function and structural improvements in pseudophakic eyes with diabetic macular oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (IluvienTM ) in a 'real world' setting. METHODS: A single centre retrospective evaluation of patients with DMO unresponsive to conventional treatment treated with the FAc implant according to UK guidelines. Primary efficacy endpoint was best corrected visual acuity (BCVA); secondary endpoints included optical coherence tomography evaluations of the macula (a) central retinal and (b) peak macular thickness collected at annual time points...
February 27, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29485235/extension-of-peripheral-nonperfusion-in-eyes-with-retinal-vein-occlusion-during-intravitreal-dexamethasone-treatment
#20
Sandra Rezar-Dreindl, Katharina Eibenberger, Wolf Buehl, Günther Weigert, Michael Georgopoulos, Ursula Schmidt-Erfurth, Stefan Sacu
BACKGROUND: To evaluate the change in peripheral perfusion status in patients with retinal vein occlusion (RVO) during dexamethasone treatment. METHODS: Thirty-five eyes of patients with macular oedema due to either branch or central retinal vein occlusion were included. At baseline, patients were treated with an intravitreal dexamethasone implant (Ozurdex® ) and followed until month 6. Wide-field angiographies were classified as ischaemic and nonischaemic. Peripheral nonperfusion (PNP) was determined manually by calculating the percentage of nonperfusion area in relation to the total visible retina (ischaemic index)...
February 27, 2018: Acta Ophthalmologica
keyword
keyword
99632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"